Approval · Notice of Compliance 1798 · 1999

FLOVENT: Notice of Compliance 1798

Issued June 29, 1999

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 1798
Date: June 29, 1999
Company: Glaxo Wellcome Inc.Mississauga, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Therapeutic class: Corticosteroid for inhalation

Products in this notice

Brand	DIN	Status today
FLOVENT	02213583	Cancelled Post Market
FLOVENT	02213591	Cancelled Post Market
FLOVENT	02213605	Cancelled Post Market
FLOVENT	02213613	Cancelled Post Market

Medicinal ingredients

FLUTICASONE PROPIONATE 25 MCG per ACT
FLUTICASONE PROPIONATE 50 MCG per ACT
FLUTICASONE PROPIONATE 125 MCG per ACT
FLUTICASONE PROPIONATE 250 MCG per ACT